dexcom g7  (Dexcom Inc)

Journal: Cancer Research Communications

Article Title: Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8 + T Cells

doi: 10.1158/2767-9764.CRC-26-0175

Figure Lengend Snippet: Vidu increases activation marker expression by tumor-specific CD8 + T cells. OT-1 splenocytes were cultured with either media (unstimulated) or E.G7-OVA cells (stimulated) for 1 hour, followed by no additional treatment (untreated) or the addition of Vidu and αQβ (treated). After 3 days of coculture, activation marker expression by OT-1 CD8 + T cells was analyzed by multicolor spectral flow cytometry. A, Representative histograms of CD25 expression on OT-1 CD8 + T cells. B, Frequency of CD25 + OT-1 CD8 + T cells and ( C ) MdFI of CD25 expression ( n = 8 mice/group) in untreated (black) and treated (red) samples. D, Representative histograms of PD-1 expression on OT-1 CD8 + T cells. E, Frequency of PD-1 + OT-1 CD8 + T cells and ( F ) MdFI of PD-1 expression ( n = 11 mice/group). G, Representative histograms of intracellular IFNγ expression by OT-1 CD8 + T cells. H, Frequency of IFNγ + OT-1 CD8 + T cells and ( I ) MdFI of IFNγ expression ( n = 11 mice/group). J, Representative histograms of intracellular TNFα expression by OT-1 CD8 + T cells. K, Frequency of TNFα + OT-1 CD8 + T cells and ( L ) MdFI of TNFα expression ( n = 6 mice/group). M, Representative histogram and dot plot and ( N ) frequency of polyfunctional IFNγ + TNFα + OT-1 CD8 + T cells ( n = 7 mice/group). Each symbol connected by a line represents an individual mouse in untreated and Vidu/αQβ conditions and the mean of the group, with error bars indicating the SEM. Statistical significance was determined using a paired t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Article Snippet: EL4 (cat. #TIB-39, RRID: CVCL_0255) and E.G7-OVA (cat. #CRL-2113, RRID: CVCL_3505) cell lines were obtained from the American Type Culture Collection and stored in liquid nitrogen tanks in the Weiner Laboratory.

Techniques: Activation Assay, Marker, Expressing, Cell Culture, Flow Cytometry

Journal: Cancer Research Communications

Article Title: Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8 + T Cells

doi: 10.1158/2767-9764.CRC-26-0175

Figure Lengend Snippet: Vidu decreases proliferation of tumor-specific CD8 + T cells while enhancing activation of cells that divided. OT-1 splenocytes were labeled with a proliferation tracking dye (CellTrace Violet) and cultured with either media (unstimulated) or E.G7-OVA cells (stimulated) for 1 hour, followed by no additional treatment (untreated) or the addition of Vidu and αQβ (treated). After 3 days of coculture, proliferation and activation marker expression by OT-1 CD8 + T cells was analyzed by multicolor spectral flow cytometry. A, Percent divided and ( B ) proliferation index of OT-1 CD8 + T cells ( n = 10 mice/group). C, Representative histograms showing OT-1 CD8 + T-cell proliferation. D, MdFI of IFNγ expression by undivided and divided OT-1 CD8 + T cells ( n = 10 mice/group) and ( E ) representative dot plot and histogram in unstimulated (blue), stimulated/untreated (black), and stimulated/treated (red) samples. F, MdFI of TNFα expression by undivided and divided OT-1 CD8 + T cells ( n = 4 mice/group) and ( G ) representative dot plot and histogram. H, MdFI of PD-1 expression by undivided and divided OT-1 CD8 + T cells ( n = 10 mice/group) and ( I ) representative dot plot and histogram. J, MdFI of CD25 expression by undivided and divided OT-1 CD8 + T cells ( n = 7 mice/group) and ( K ) representative dot plot and histogram. E , G , I , and K, Red arrows indicate undivided population, and vertical dashed lines indicate separation of negative (left) from positive (right) marker expression. Each symbol connected by a line represents an individual mouse in untreated and Vidu/αQβ conditions and the mean of the group, with error bars indicating the SEM. Statistical significance was determined using a paired t test ( A and B ) or two-way ANOVA with Sidak multiple comparisons test ( D–J ): *, P < 0.05; **, P < 0.01; ****, P < 0.0001; ns, not significant.

Article Snippet: EL4 (cat. #TIB-39, RRID: CVCL_0255) and E.G7-OVA (cat. #CRL-2113, RRID: CVCL_3505) cell lines were obtained from the American Type Culture Collection and stored in liquid nitrogen tanks in the Weiner Laboratory.

Techniques: Activation Assay, Labeling, Cell Culture, Marker, Expressing, Flow Cytometry

Journal: Cancer Research Communications

Article Title: Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8 + T Cells

doi: 10.1158/2767-9764.CRC-26-0175

Figure Lengend Snippet: Vidu modestly increases granzyme B expression by tumor-specific CD8 + T cells but has limited impact on cytotoxicity. OT-1 splenocytes were cultured with E.G7-OVA cells or SIINFEKL peptide (stimulated) for 1 hour, followed by no additional treatment (untreated) or the addition of Vidu and αQβ (treated). After 3 days of coculture, granzyme B expression or cytotoxicity by OT-1 CD8 + T cells was analyzed. A, Frequency of granzyme B + OT-1 CD8 + T cells and MdFI of granzyme B expression ( n = 5 mice/group) in untreated (black) and treated (red) samples. B, Secreted granzyme B as determined by ELISA ( n = 3 mice/group). C, treatment and cytotoxicity schema of ( D and E ) isolated CD8 + T cells were cocultured with target E.G7-OVA tumor cells at various effector:target ratios for 18 hours. D, Percent cytotoxicity of OT-1 CD8 + T cells and ( E ) viable E.G7-OVA cells/mL was determined ( n = 3–4 mice/group). SIINFEKL peptide was used at a final concentration of 10 ng/mL. Each symbol connected by a line represents an individual mouse in untreated and Vidu/αQβ conditions and the mean of the group, with error bars indicating the SEM. Statistical significance was determined using a paired t test: *, P < 0.05; **, P < 0.01; ns, not significant. [ C, Created in BioRender. Weiner, G. (2026) https://BioRender.com/s3vjcvy .]

Article Snippet: EL4 (cat. #TIB-39, RRID: CVCL_0255) and E.G7-OVA (cat. #CRL-2113, RRID: CVCL_3505) cell lines were obtained from the American Type Culture Collection and stored in liquid nitrogen tanks in the Weiner Laboratory.

Techniques: Expressing, Cell Culture, Enzyme-linked Immunosorbent Assay, Isolation, Concentration Assay

Journal: Cancer Research Communications

Article Title: Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8 + T Cells

doi: 10.1158/2767-9764.CRC-26-0175

Figure Lengend Snippet: Vidu enhances triple-positive tumor-specific CD8 + T-cell activation marker expression after culture with target cells for 3 days. OT-1 splenocytes were cultured with either media (unstimulated) or E.G7-OVA cells (stimulated) for 1 hour, followed by no additional treatment (untreated) or the addition of Vidu and αQβ (treated). After 3 days of coculture, activation and exhaustion marker expression by OT-1 CD8 + T cells was analyzed by multicolor spectral flow cytometry. A, Representative dot plot and histogram in unstimulated (blue), stimulated/untreated (black), and stimulated/treated (red) samples showing the gating strategy of PD-1 + OT-1 CD8 + T cells and their coexpression of LAG3 ± TIM3. B, Double- and triple-positive OT-1 CD8 + T-cell populations were analyzed for activation marker expression in untreated (black) and treated (red) samples ( n = 8 mice/group). C, Frequency of CD25 + OT-1 CD8 + T cells and ( D ) MdFI of CD25 expression ( n = 8 mice/group). E, Frequency of IFNγ + OT-1 CD8 + T cells and ( F ) MdFI of IFNγ expression ( n = 8 mice/group). G, Frequency of IFNγ + TNFα + OT-1 CD8 + T cells ( n = 5 mice/group). Each symbol connected by a line represents an individual mouse in untreated and Vidu/αQβ conditions and the mean of the group, with error bars indicating the SEM. Statistical significance was determined using a two-way ANOVA with Sidak multiple comparisons test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

Article Snippet: EL4 (cat. #TIB-39, RRID: CVCL_0255) and E.G7-OVA (cat. #CRL-2113, RRID: CVCL_3505) cell lines were obtained from the American Type Culture Collection and stored in liquid nitrogen tanks in the Weiner Laboratory.

Techniques: Activation Assay, Marker, Expressing, Cell Culture, Flow Cytometry

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: Rational modulation of tumor microenvironment enhances therapeutic responsiveness to αOX40-based immunotherapy (A–D) OX40-humanized mice bearing subcutaneous MC38 (A), B16 (B), E.G7 (C), or KPC (D) tumors ( n = 5–7 mice per group). Tumor growth curves (numbers indicate complete cures) and Kaplan-Meier survival for each model. Treatments: MPLA+IFN-γ ( i.t. , intratumoral); Combo: MPLA+IFN-γ ( i.t. , intratumoral) + αOX40 ( i.p. , intraperitoneal). (E) Study schema of secondary tumor challenge in MC38 model treated with Combo. (F) Tumor progression and survival outcomes following secondary tumor challenge. Growth kinetics of re-implanted tumors in tumor-cleared mice (previously cured by therapy) versus treatment-naive wild-type controls (left). Kaplan-Meier survival plot (right) ( n = 13 mice per group). (G) Systemic immunity evaluation schema with bilateral MC38 bearing mice were treated with Combo, αOX40, and control. (H) Tumor growth curves and survival plots of (G) ( n = 6–7 mice per group). Data are shown as means ± SD from one of two independent experiments (A–D, F, and H). Statistical significance was determined using log rank test (A–H). n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The mouse melanoma B16-F10 (Cat# CRL-6475) and mouse T lymphoma E.G7 (Cat# CRL-2113) cell lines were purchased from ATCC.

Techniques: Control

Journal: Cell Reports Medicine

Article Title: Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

doi: 10.1016/j.xcrm.2026.102699

Figure Lengend Snippet: Rational modulation of tumor microenvironment enhances therapeutic responsiveness to αOX40-based immunotherapy (A–D) OX40-humanized mice bearing subcutaneous MC38 (A), B16 (B), E.G7 (C), or KPC (D) tumors ( n = 5–7 mice per group). Tumor growth curves (numbers indicate complete cures) and Kaplan-Meier survival for each model. Treatments: MPLA+IFN-γ ( i.t. , intratumoral); Combo: MPLA+IFN-γ ( i.t. , intratumoral) + αOX40 ( i.p. , intraperitoneal). (E) Study schema of secondary tumor challenge in MC38 model treated with Combo. (F) Tumor progression and survival outcomes following secondary tumor challenge. Growth kinetics of re-implanted tumors in tumor-cleared mice (previously cured by therapy) versus treatment-naive wild-type controls (left). Kaplan-Meier survival plot (right) ( n = 13 mice per group). (G) Systemic immunity evaluation schema with bilateral MC38 bearing mice were treated with Combo, αOX40, and control. (H) Tumor growth curves and survival plots of (G) ( n = 6–7 mice per group). Data are shown as means ± SD from one of two independent experiments (A–D, F, and H). Statistical significance was determined using log rank test (A–H). n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: E.G7 Mouse T lymphoma Cell , ATCC , Cat# CRL-2113.

Techniques: Control